CN108721214A - How appropriate pyrrole is smooth and palonosetron compound nanoparticle solution, nanoparticle and preparation method and purposes - Google Patents
How appropriate pyrrole is smooth and palonosetron compound nanoparticle solution, nanoparticle and preparation method and purposes Download PDFInfo
- Publication number
- CN108721214A CN108721214A CN201710244005.2A CN201710244005A CN108721214A CN 108721214 A CN108721214 A CN 108721214A CN 201710244005 A CN201710244005 A CN 201710244005A CN 108721214 A CN108721214 A CN 108721214A
- Authority
- CN
- China
- Prior art keywords
- palonosetron
- smooth
- solution
- appropriate pyrrole
- pyrrole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title claims abstract description 214
- 229960002131 palonosetron Drugs 0.000 title claims abstract description 112
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 92
- -1 palonosetron compound Chemical class 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002552 dosage form Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 63
- 239000002994 raw material Substances 0.000 claims description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 229920001577 copolymer Polymers 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000004698 Polyethylene Substances 0.000 claims description 12
- 206010047700 Vomiting Diseases 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 229920000573 polyethylene Polymers 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000002512 chemotherapy Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 8
- 239000000310 rehydration solution Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 229920001610 polycaprolactone Polymers 0.000 claims description 6
- 239000004632 polycaprolactone Substances 0.000 claims description 6
- 239000004626 polylactic acid Substances 0.000 claims description 6
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 239000000644 isotonic solution Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229940049964 oleate Drugs 0.000 claims description 4
- 239000003340 retarding agent Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 3
- 229950005499 carbon tetrachloride Drugs 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 230000003139 buffering effect Effects 0.000 claims description 2
- 229940114081 cinnamate Drugs 0.000 claims description 2
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
- 229940049918 linoleate Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- LRWJZGCOPMDWFZ-UHFFFAOYSA-N phthalic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1C(O)=O LRWJZGCOPMDWFZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 239000007974 sodium acetate buffer Substances 0.000 claims description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 239000007981 phosphate-citrate buffer Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 6
- 238000004108 freeze drying Methods 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000009513 drug distribution Methods 0.000 abstract description 3
- 230000003474 anti-emetic effect Effects 0.000 abstract description 2
- 239000002111 antiemetic agent Substances 0.000 abstract description 2
- 238000013459 approach Methods 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 235000013339 cereals Nutrition 0.000 description 9
- 238000001338 self-assembly Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100037346 Substance-P receptor Human genes 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- CPZBLNMUGSZIPR-RDJZCZTQSA-N (3ar)-2-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3h-benzo[de]isoquinolin-1-one Chemical compound C1N(CC2)CCC2[C@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@@H]3C1 CPZBLNMUGSZIPR-RDJZCZTQSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical class CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940024224 palonosetron 0.5 mg Drugs 0.000 description 1
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to field of medicaments, and in particular to using how appropriate pyrrole is smooth and palonosetron is how appropriate a kind of new and effective antiemetic compound medicine pyrrole that active constituent is prepared be smooth with palonosetron compound drug-carrying nanometer particle, nanoparticle solution.The technical problem to be solved by the present invention is to improve how appropriate pyrrole is smooth and the water solubility of palonosetron, drug is made to reach slow releasing function in vivo, improves the biological utilisation of drug, changes drug distribution, improve curative effect.To realize how appropriate pyrrole is smooth a variety of dosage forms can be made with palonosetron compound preparation provide new method and new approaches.The compound nanoparticle has many advantages, such as that good water solubility, epigranular, character are stable, freeze-drying is easily redissolved, is easily absorbed, can be injected intravenously.
Description
Technical field
The invention belongs to field of medicaments, and in particular to a kind of how appropriate pyrrole is smooth molten with palonosetron compound drug-carrying nanometer particle
Liquid, nanoparticle and preparation method thereof.Cancer can be treated by injection or be alleviated to the compound drug-carrying nanometer particle solution or nanoparticle
The nausea and vomiting symptom that disease patient occurs in chemotherapy, radiotherapy, operation.
Background technology
Chemotherapy is one of the means of current treatment malignant tumour, however has 75% or more chemotherapy patients that difference can all occur
The Nausea and vomiting (CINV) of degree.This adverse reaction can not only influence the quality of life of patient, reduce the compliance of patient,
Serious vomiter can also cause that Water-Electrolyte is unbalance, nutritional deficiency, to keep tumour control undesirable.In addition to this, nausea and vomiting
Common one of side effect when being tumor radiotherapy, most of is because caused by gastrointestinal dysfunction caused by radiotherapy.Therefore logical
The important content that drug is crossed come the generation of Nausea and vomiting during preventing or reducing radiotherapy, chemotherapy as tumor patient supportive treatment.
How appropriate pyrrole smooth (netuppitant) is a kind of new drug, as a kind of nk 1 receptor retarding agent, can effectively be given protection against cancer in advance
The nausea and vomiting that disease chemotherapy acute stage and period of delay generate (in startup chemotherapy 25~120 hours).How the smooth chinesization of appropriate pyrrole
Scientific name claims：2- [3,5- bis- (trifluoromethyl) phenyl]-N, 2- dimethyl-N -s [(shout -1- 4- (2- aminomethyl phenyls) -6- by 4- methyl piperazines
Base) pyridin-3-yl] propionamide；English language Chemical name：2-[3,5-bis(trifluoromethyl)phenyl]-N,2-
dimethy-N-l[4-(2-methylphenyl)-6-(4-methyIpiperaz in-l-yl)pyridin-3-yI]
propanamide；Molecular weight：578.60；Molecular formula：C30 H32 F6N4O；CAS registration numbers：290297-26-6.
Palonosetron (palonosetron) is a kind of inhibition nausea and vomiting medicine, belongs to novel highly selective, high affine
Property 5-HT3 receptor antagonists, it can block the excitement of the presynaptic 5-HT receptor of vomiting reflex maincenter peripheral neurons, and directly
The effect got excited through vagus nerve successor back zone that 5-HT receptor agonisms in central nervous system generate is influenced, is blocked in enteron aisle
Vagus nerve ending prevents signal from being transferred to 5-HT receptor trigger regions, reduces the incidence of nausea and vomiting.It is clinically used to control
It treats in, severe causes acute, retardance nausea and vomiting caused by spitting property chemotherapeutics.Because it is with curative effect height, toxic side effect
Small, long half time (about 40h), the features such as dosage is small and be concerned.In July, 2003, palonosetron is because of its long-term effect
With it is highly selective become the 1st be approved by the fda in the United States for moderate cause vomitting property chemotherapeutics caused by retardance Nausea and vomiting
Prophylactic agent.It is also the 4th 5-HT3 receptor antagonist for being approved for treating acute CINV, while also going through to use
In the prevention of postoperative nauseaand vomiting (PONV).
The Chinese chemical name of palonosetron：(3aS) -2- [(S)-l- azabicyclics [2.2.2] oct-3-yl] -2,3,
3a, 4,5,6- hexahydro -1- oxo -1H- benzos [de] isoquinolin；English language Chemical title:[R-(R*,R*)]-2-(1-
Azabicyclo[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-
one；Molecular weight：296.41；Molecular formula：C19H24N2O；CAS registration numbers：149653-99-6.
Nano medication possesses the advantage not available for many conventional medicaments, simultaneously because its used carrier and modification side
Method wide variety, the exploitation for updating better function is that potential is huge.Nanoparticle generally use amphiphilic copolymer is made
It for carrier material, is prepared by way of self assembly, the solubility of insoluble drug in water can be obviously improved.Have
Good water-soluble, biocompatibility and biodegradability while the circulation time of drug in blood is also added, controllably
Pharmacy object sustained release and targeted delivery, to increase drug effect, reduce side effect.Currently, Nano medication is solving indissoluble
Property drug solubility and improve drug bioavailability research field obtain extensive concern.
Invention content
For how the defect of the smooth poorly water-soluble of appropriate pyrrole, the present invention is by way of self assembly with amphiphilic block polymer packet
Wrap up in how appropriate pyrrole is smooth and palonosetron, ultimately form how appropriate pyrrole is smooth and the load medicine compound nanoparticle solution of palonosetron, receives
The grain of rice.Method through the invention had both improved how appropriate pyrrole is smooth and the water solubility of palonosetron, and drug is made to reach slow in vivo
Effect is released, the biological utilisation of drug is improved, changes drug distribution, improves curative effect.
The present invention wraps up how appropriate pyrrole is smooth and palonosetron using amphipathic nature block polymer, utilizes the method for self assembly
Prepare a kind of novel water-soluble compound nanoparticle.The compound nanoparticle has water-soluble good, epigranular, character steady
Fixed, freeze-drying is easily redissolved, is easily absorbed, bioavilability is high, the advantages that being injected intravenously.
First problem to be solved by this invention is to provide a kind of how appropriate pyrrole is smooth and palonosetron compound nanoparticle is molten
The preparation method of liquid,
Raw material：Raw material A is how appropriate pyrrole is smooth, and raw material B is palonosetron, palonosetron optical isomer or Pa Luonuosi
Any one in agar soluble, raw material C are that methoxy polyethylene glycol-polylactic acid (mPEG-PLA) copolymer, monomethyl ether are poly-
Ethylene glycol-polycaprolactone (mPEG-PCL) copolymer, polycaprolactone-polyethylene glycol-polycaprolactone (PCL-PEG-PCL) copolymerization
In object, polylactide-polyethylene glycol-polylactic acid (PLA-PEG-PLA) copolymer, polylactic acid-glycolic acid (PLA-PGA) copolymer
It is at least one；
Solvent：Dichloromethane, chloroform, acetone, tetrachloromethane, ethyl alcohol, methanol, ether, petroleum ether, pentane, ethyl acetate
Or at least one of hexamethylene；
Rehydration solution：At least one of pure water, isotonic solution or buffer solution；
Preparation method：Raw material A, raw material B and raw material C are distinguished into dissolving and mixing in a solvent, then remove solvent,
It is complete to aquation that rehydration solution is added, acquired solution is that how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution.
Preferably, above-mentioned how appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution, raw material A ︰ raw materials C=
0.001~0.256, raw material B ︰ raw materials C=0.001~0.0256.
Preferably, above-mentioned how appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution, the Pa Luonuo
It is arbitrary in oleate, stearate, palmitate, linoleate, laruate or cinnamate to take charge of agar soluble
It is a kind of.
Preferably, above-mentioned how appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution, the described equal vadose solutions
Liquid is selected from least one of physiological saline, 5% glucose solution or 0.149mol/L sodium bicarbonate solutions.
It is preferably, above-mentioned that how appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution, the buffering are molten
Liquid is selected from phosphate buffer, acetic acid-sodium acetate buffer solution, citric acid-sodium citrate buffer solution, disodium hydrogen phosphate-citric acid
At least one of buffer solution or phthalic acid-hydrochloride buffer.
How appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution is prepared into the present invention also provides above-mentioned
Arrive how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution.
The present invention also provides how appropriate pyrrole is smooth and palonosetron compound nanoparticle, by how appropriate transparency liquid pyrrole be smooth and pa Lip river
Nuo Siqiong compound nanoparticle solution is drying to obtain how appropriate pyrrole is smooth and palonosetron compound nanoparticle.
How appropriate pyrrole is smooth and the epigranular of palonosetron compound nanoparticle for gained of the invention, average grain diameter be 95nm ±
10nm, average potential are+1.35 ± 0.21mV, and favorable solubility, character are stable in aqueous solution and freeze-drying can redissolve.
The present invention also provides how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution or described how appropriate pyrrole is smooth by above-mentioned
Any pharmaceutical dosage form being prepared with palonosetron compound nanoparticle.
The present invention also provides by it is above-mentioned how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution or state how appropriate pyrrole
Ejection preparation made of smooth and above-mentioned palonosetron compound nanoparticle.
The ejection preparation includes injection with small volume, high-capacity injection or injection freeze-dried powder etc..
How appropriate pyrrole is smooth and palonosetron compound nanoparticle solution, how appropriate pyrrole is smooth and pa Lip river the present invention also provides above-mentioned
Purposes of the Nuo Siqiong compounds nanoparticle in preparing nk 1 receptor retarding agent.
How appropriate pyrrole is smooth and palonosetron compound nanoparticle solution, how appropriate pyrrole is smooth and pa Lip river the present invention also provides above-mentioned
Purposes of the Nuo Siqiong compounds nanoparticle in preparing treatment or alleviating the drug of Nausea and vomiting caused by chemotherapy.
With amphiphilic copolymer package, how appropriate pyrrole is smooth and palonosetron by the way of self assembly for the method for the present invention, hence it is evident that
Improve how appropriate pyrrole is smooth and the water solubility of palonosetron, so that drug is reached slow releasing function in vivo, improve the biology of drug
It utilizes, changes drug distribution, improve curative effect.Using most preferably proportioning be prepared how appropriate pyrrole is smooth and palonosetron
How appropriate pyrrole is smooth in compound nanoparticle and the solubility maximum of palonosetron in aqueous solution can respectively reach about 20mg/mL,
2mg/mL significantly improves how appropriate pyrrole is smooth and the water solubility of palonosetron.
Since how appropriate pyrrole is smooth very poor so being wrapped up from group using amphiphilic block polymer with the water solubility of palonosetron
It fills the method for forming nanoparticle and not only effectively significantly improves how appropriate pyrrole is smooth and the water solubility of palonosetron, and enhance
How appropriate pyrrole is smooth and two drugs of palonosetron are in antiemetic, alleviates the drug synergism of nausea, change how appropriate pyrrole it is smooth and
The distribution of palonosetron in vivo improves curative effect.In addition to this, the limitation that the method overcome drugs in dosage form, can
Drug is made any desired preparation, such as injection realization intravenous injection, drug passed through in the form of nanoparticle quiet
Arteries and veins injection reaches the release of controllable drug in vivo, reaches slow releasing function in vivo.
Description of the drawings
The molecular structural formula of Fig. 1, (A) mPEG-PLA；(B) how the smooth molecular structural formula of appropriate pyrrole；(C) point of palonosetron
Subformula；
Fig. 2, how appropriate pyrrole is smooth and palonosetron compound nanoparticle self assembly schematic diagram；
Fig. 3, how appropriate pyrrole is smooth and the grain size distribution of palonosetron compound nanoparticle；
Fig. 4, how appropriate pyrrole is smooth and the potential image of palonosetron compound nanoparticle；
Fig. 5, how appropriate pyrrole is smooth and the scanning transmission electron microscope figure of palonosetron compound nanoparticle；
Fig. 6, using the fat-soluble salt of palonosetron as the preparation process schematic diagram of raw material.
Specific implementation mode
Since how appropriate pyrrole is smooth and palonosetron poorly water-soluble, it is difficult to will how appropriate pyrrole be smooth and palonosetron is prepared into compound
Pharmaceutical solutions.It has been investigated that will how appropriate pyrrole is smooth and palonosetron is wrapped up by amphiphilic block polymer, using self assembly
Mode be prepared into nanoparticle and not only solved the problems, such as how appropriate pyrrole is smooth and palonosetron poorly water-soluble but also how appropriate improved
The smooth collaboration pharmacological action with palonosetron of pyrrole, improves drug effect.
How appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution, is prepared in the following manner：
Raw material：Raw material A is how appropriate pyrrole is smooth, and raw material B is palonosetron, palonosetron optical isomer or Pa Luonuosi
Any one in agar soluble, raw material C are that methoxy polyethylene glycol-polylactic acid (mPEG-PLA) copolymer, monomethyl ether are poly-
Ethylene glycol-polycaprolactone (mPEG-PCL) copolymer, polycaprolactone-polyethylene glycol-polycaprolactone (PCL-PEG-PCL) copolymerization
In object, polylactide-polyethylene glycol-polylactic acid (PLA-PEG-PLA) copolymer, polylactic acid-glycolic acid (PLA-PGA) copolymer
It is at least one；
Solvent：Dichloromethane, chloroform, acetone, tetrachloromethane, ethyl alcohol, methanol, ether, petroleum ether, pentane, ethyl acetate
Or at least one of hexamethylene；
Rehydration solution：At least one of pure water, isotonic solution or buffer solution；
Preparation method：Raw material A, raw material B and raw material C are distinguished into dissolving and mixing in a solvent, then pass through rotation
The mode of evaporation removes solvent, be added appropriate rehydration solution slightly concussion it is complete to aquation, acquired solution be how appropriate pyrrole it is smooth and
Palonosetron compound nanoparticle solution.
Inventor has found through overtesting, when raw material A ︰ raw materials C=0.001~0.256, raw material B ︰ raw materials C=0.001~
0.0256, by way of self assembly, raw material C can be by the transparent nanoparticle solution of raw material A, the fully wrapped around formation of B.If matter
When amount is than higher than aforementioned proportion, then raw material A or B are on the high side, and nanoparticle self assembly effect is bad, drug can not be made to form nanometer completely
Grain.In above-mentioned digital scope, i.e. raw material A ︰ raw materials C=0.001~0.256, raw material B ︰ raw materials C=0.001~0.0256 can
According to the proportionate relationship for requiring optionally to adjust each substance.
How appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution is prepared into the present invention also provides above-mentioned
Arrive how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution.
The present invention also provides how appropriate pyrrole is smooth and palonosetron compound nanoparticle, by how appropriate transparency liquid pyrrole be smooth and pa Lip river
Nuo Siqiong compound nanoparticle solution is drying to obtain how appropriate pyrrole is smooth and palonosetron compound nanoparticle.
How appropriate pyrrole is smooth and the epigranular of palonosetron compound nanoparticle for gained of the invention, average grain diameter be 95nm ±
10nm, average potential are+1.35 ± 0.21mV, and character is stable in rehydration solution and freeze-drying can redissolve.
The present invention also provides how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution or above-mentioned how appropriate pyrrole is smooth by above-mentioned
Any pharmaceutical formulation prepared with palonosetron compound nanoparticle.
The present invention also provides how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution or above-mentioned how appropriate pyrrole is smooth by described
The ejection preparation being prepared with palonosetron compound nanoparticle.The ejection preparation includes injection with small volume, large capacity
Injection, injection freeze-dried powder etc..
How appropriate pyrrole is smooth and palonosetron compound nanoparticle solution or above-mentioned how appropriate pyrrole is smooth the present invention also provides above-mentioned
With purposes of the palonosetron compound nanoparticle in preparing nk 1 receptor retarding agent.
How appropriate pyrrole is smooth and palonosetron compound nanoparticle solution or above-mentioned how appropriate pyrrole is smooth the present invention also provides above-mentioned
With purposes of the palonosetron compound nanoparticle in preparing treatment or alleviating the drug of Nausea and vomiting caused by chemotherapy.
The preparation method of the fat-soluble salt of palonosetron involved in the present invention is approximately as by taking oleic acid as an example：By hydrochloric acid
Palonosetron dissolves in water, and oleic acid is dissolved in organic solvent (such as dichloromethane), then in molar ratio 1：1 amount is molten in oleic acid
Equimolar NaOH is added in liquid, both palonosetron Hcl aqueous solution and oleic acid solutions are mixed, add methanol mixing extremely
Solution is clarified, and suitable quantity of water and organic solvent (such as dichloromethane) are then added, and solution will be layered at this time, is removed water layer, is stayed
Under organic layer be containing palonosetron oleate solution (that is, palonosetron oleate be dissolved in it is organic molten
In agent).Same procedure preparation can be used in the fat-soluble salt of other palonosetrons.
Embodiment 1
It takes after how the smooth 5mg of appropriate pyrrole, palonosetron 1mg, mPEG-PCL copolymer 94mg be dissolved in respectively in 5mL dichloromethane
It is mixed in round-bottomed flask, removes the pure water 1mL of 60 DEG C of addition after organic reagent with Rotary Evaporators at 60 DEG C, it is slight to shake
It swings, until aquation is complete, forms how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution.How appropriate the pyrrole be smooth and palonosetron
Obtain how appropriate pyrrole is smooth and palonosetron compound nanoparticle after the drying of compound nanoparticle solution.
Embodiment 2
Take how the smooth 3mg of appropriate pyrrole, palonosetron 0.5mg, PLA-PGA copolymer 96.5mg are dissolved in 5mL dichloromethane respectively
In after be mixed in round-bottomed flask, 60 DEG C of pure water 1mL is added after removing organic reagent with Rotary Evaporators at 60 DEG C, slightly
Concussion forms how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution until aquation is complete.How appropriate the pyrrole be smooth and Pa Luonuosi
Obtain how appropriate pyrrole is smooth and palonosetron compound nanoparticle after the drying of fine jade compound nanoparticle solution.
Embodiment 3
Take how the smooth 20mg of appropriate pyrrole, palonosetron 2mg, mPEG-PLA copolymer 78mg are dissolved in respectively in 5mL dichloromethane
After be mixed in round-bottomed flask, 60 DEG C of pure water 1mL is added after removing organic reagent with Rotary Evaporators at 60 DEG C, it is slight to shake
It swings, until aquation is complete, forms how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution.How appropriate the pyrrole be smooth and palonosetron
Obtain how appropriate pyrrole is smooth and palonosetron compound nanoparticle after the drying of compound nanoparticle solution.
Shown in characterization collection of illustrative plates following Fig. 3,4,5 of 3 gained drug-carrying nanometer particle of embodiment.Wherein Fig. 3 is that how appropriate pyrrole is smooth and pa
The grain size distribution of palonosetron compound nanoparticle；From the figure 3, it may be seen that obtained nanoparticle epigranular, average grain diameter reach
95nm±10nm.Fig. 4 is that how appropriate pyrrole is smooth and the potential image of palonosetron compound nanoparticle；Wherein measure the nanoparticle
Average potential is 1.35 ± 0.21mV.Fig. 5 is that how appropriate pyrrole is smooth and the scanning transmission electron microscope figure of palonosetron compound nanoparticle；By
Nanoparticle known to the figure is uniformly dispersed, and grain size is small, reaches 100nm or so.
The present invention is also to how appropriate pyrrole is smooth, the nanoparticle of palonosetron and the present invention have carried out appearance comparison, as a result such as
Under：It is single that how the smooth bulk pharmaceutical chemicals of appropriate pyrrole are dispersed in water (Wt=20mg/mL is dispersed in how appropriate 20mg pyrroles be smooth in 1mL water),
Drug exists all in the form of crystal in water, solutions turbid；Single palonosetron be dispersed in water (Wt=2mg/mL, i.e.,
2mg palonosetrons are dispersed in 1mL water), drug exists all in the form of crystal in water, solutions turbid；Nanometer of the present invention
Grain is dispersed in water, and solution clarification and general light opalescence, solution still clarifies no precipitation after standing a period of time.
Claims (12)
1. how appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution, it is characterised in that：
Raw material：Raw material A is how appropriate pyrrole is smooth, and raw material B is palonosetron, palonosetron optical isomer or palonosetron fat
Any one in soluble, raw material C are methoxy polyethylene glycol-polylactic acid copolymer, monomethyl ether polyethylene glycol-polycaprolactone
Copolymer, polycaprolactone-polyethylene glycol-polycaprolactone copolymer, polylactide-polyethylene glycol-polylactic acid copolymer, polylactic acid-
Any one in glycol acid copolymer；
Solvent：Dichloromethane, chloroform, acetone, tetrachloromethane, ethyl alcohol, methanol, ether, petroleum ether, pentane, ethyl acetate or ring
At least one of hexane；
Rehydration solution：At least one of pure water, isotonic solution or buffer solution；
Preparation method：Raw material A, raw material B and raw material C are distinguished into dissolving and mixing in a solvent, solvent is then removed, is added
Rehydration solution is complete to aquation, and acquired solution is that how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution.
2. according to claim 1, how appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution, feature
It is：It counts by weight ratio, raw material A ︰ raw materials C=0.001~0.256, raw material B ︰ raw materials C=0.001~0.0256.
3. according to claim 1 or 2, how appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution, special
Sign is：The fat-soluble salt of the palonosetron is selected from oleate, stearate, palmitate, linoleate, laruate
Or any one in cinnamate.
4. according to claim 1 or 2, how appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution, special
Sign is：The isotonic solution in physiological saline, 5% glucose solution or 0.149mol/L sodium bicarbonate solutions extremely
Few one kind.
5. according to claim 1 or 2, how appropriate pyrrole is smooth and the preparation method of palonosetron compound nanoparticle solution, special
Sign is：The buffer solution is selected from phosphate buffer, acetic acid-sodium acetate buffer solution, citric acid-sodium citrate buffering
At least one of liquid, disodium hydrogen phosphate-citrate buffer solution or phthalic acid-hydrochloride buffer.
6. by the smooth preparation method with palonosetron compound nanoparticle solution of the how appropriate pyrrole of Claims 1 to 5 any one of them
Be prepared how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution.
7. how appropriate pyrrole is smooth and palonosetron compound nanoparticle, it is characterised in that：By described in claim 6 how appropriate pyrrole is smooth and pa
Palonosetron compound nanoparticle solution is dried to obtain.
8. by described in claim 6 how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution or claim 7 described in how
The smooth any pharmaceutical dosage form being prepared with palonosetron compound nanoparticle of appropriate pyrrole.
9. by described in claim 6 how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution or claim 7 described in how
The smooth ejection preparation being prepared with palonosetron compound nanoparticle of appropriate pyrrole.
10. the ejection preparation described in claim 9 includes injection with small volume, high-capacity injection or injection freeze-dried powder.
11. described in claim 6 how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution or claim 7 described in it is how appropriate
Pyrrole is smooth and purposes of the palonosetron compound nanoparticle in preparing nk 1 receptor retarding agent.
12. described in claim 6 how appropriate pyrrole is smooth and palonosetron compound nanoparticle solution or claim 7 described in it is how appropriate
The purposes that pyrrole is smooth and palonosetron compound nanoparticle is in preparing treatment or alleviating the drug of Nausea and vomiting caused by chemotherapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710244005.2A CN108721214B (en) | 2017-04-14 | 2017-04-14 | Netupidan and palonosetron compound nanoparticle solution, nanoparticles, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710244005.2A CN108721214B (en) | 2017-04-14 | 2017-04-14 | Netupidan and palonosetron compound nanoparticle solution, nanoparticles, preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108721214A true CN108721214A (en) | 2018-11-02 |
| CN108721214B CN108721214B (en) | 2020-06-16 |
Family
ID=63924455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710244005.2A Active CN108721214B (en) | 2017-04-14 | 2017-04-14 | Netupidan and palonosetron compound nanoparticle solution, nanoparticles, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108721214B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013057554A2 (en) * | 2011-10-18 | 2013-04-25 | Helsinn Healthcare Sa | Therapeutic combinations of netupitant and palonosetron |
| CN104856998A (en) * | 2009-11-18 | 2015-08-26 | 赫尔辛医疗股份公司 | Compositions for treating centrally mediated nausea and vomiting |
-
2017
- 2017-04-14 CN CN201710244005.2A patent/CN108721214B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104856998A (en) * | 2009-11-18 | 2015-08-26 | 赫尔辛医疗股份公司 | Compositions for treating centrally mediated nausea and vomiting |
| CN106421793A (en) * | 2009-11-18 | 2017-02-22 | 赫尔辛医疗股份公司 | Compositions for treating centrally mediated nausea and vomiting |
| WO2013057554A2 (en) * | 2011-10-18 | 2013-04-25 | Helsinn Healthcare Sa | Therapeutic combinations of netupitant and palonosetron |
Non-Patent Citations (2)
| Title |
|---|
| 刘建宇: "奈妥吡坦和帕洛诺司琼", 《中国药物化学杂志》 * |
| 谭光根等: "肿瘤化学疗法止吐治疗新进展", 《河北医科大学学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108721214B (en) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104114159B (en) | The polymeric excipient for being lyophilized or freezing for particle | |
| CN102908627B (en) | pH-sensitive nanoparticles for oral insulin delivery | |
| Lu et al. | Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release | |
| Xu et al. | Toward immunosuppressive effects on liver transplantation in rat model: tacrolimus loaded poly (ethylene glycol)-poly (D, L-lactide) nanoparticle with longer survival time | |
| Wang et al. | Polysorbate 80 coated poly (ɛ-caprolactone)–poly (ethylene glycol)–poly (ɛ-caprolactone) micelles for paclitaxel delivery | |
| EP2564874B1 (en) | Lyophilized formulation of pectin-adriamycin conjugate and preparation method thereof | |
| CN101084876A (en) | Anti-cancer composition containing bendamustine | |
| CN101081206A (en) | Anti-cancer medicine composition containing tyrosine kinase restraining agent | |
| CN103417515A (en) | Biodegradable nanoparticle-entrapped oral colon-targeted micro-capsule and preparation method thereof | |
| CN105384920A (en) | Selenium or tellurium containing polymer as well as preparation method and application of selenium or tellurium containing polymer | |
| Nasef et al. | Formulation and in-vitro evaluation of pantoprazole loaded pH-sensitive polymeric nanoparticles | |
| JP2010527971A (en) | Sustained release composition comprising somatostatin derivatives in microparticles | |
| RU2563997C2 (en) | Oxaliplatin nanoparticles and method of obtaining thereof | |
| CN107049944B (en) | Polymer micelle capable of realizing simultaneous administration of sorafenib and curcumin and preparation method thereof | |
| Wu et al. | Amorphous silibinin nanoparticles loaded into porous starch to enhance remarkably its solubility and bioavailability in vivo | |
| Li et al. | Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma | |
| CN100998566A (en) | Nanometer microsphere of temozolomide polylactic acid and its preparation and preparing method therefor | |
| CN103655484A (en) | Method for preparing paclitaxel sustained-release microspheres by use of self-assembly technology and product thereof | |
| CN106361724A (en) | 20(R)-ginsenoside Rg3 slow release nanometer microsphere composition, and preparation method thereof | |
| CN106983734B (en) | A kind of ibuprofen sustained release capsules and preparation method thereof | |
| CN109265658B (en) | Drug-loaded nanoparticle based on ferulic acid polymer and preparation method and application thereof | |
| CN108721214A (en) | How appropriate pyrrole is smooth and palonosetron compound nanoparticle solution, nanoparticle and preparation method and purposes | |
| CN102961322A (en) | Drug-loaded mixed micelle | |
| Zhu et al. | Bioerodable ketamine-loaded microparticles fabricated using dissolvable hydrogel template technology | |
| CN113786393A (en) | Rivaroxaban microsphere and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230524 Address after: Huitong Building, No. 3 Disheng Middle Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing, 100176 Patentee after: BEIJING FUNHAU MEDICAL TECHNOLOGY CO.,LTD. Address before: 100044 2012 doctoral student of Beijing Jiaotong University, No.3 college, Shangyuan village, Haidian District, Beijing Patentee before: He Long |